

Don R Husereau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4510174/publications.pdf>

Version: 2024-02-01

94
papers

7,557
citations

159358

30
h-index

56606

83
g-index

98
all docs

98
docs citations

98
times ranked

12195
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 336-344. | 1.1 | 26 |
| 2 | Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Journal of Medical Economics, 2022, 25, 1-7. | 1.0 | 9 |
| 3 | Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ, The, 2022, 376, e067975. | 3.0 | 141 |
| 4 | Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Pharmacoeconomics, 2022, 40, 601-609. | 1.7 | 39 |
| 5 | Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. Value in Health, 2022, 25, 10-31. | 0.1 | 251 |
| 6 | Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Public Health, 2022, 22, 179. | 1.2 | 7 |
| 7 | Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Journal of Managed Care & Specialty Pharmacy, 2022, , 1-10. | 0.5 | 0 |
| 8 | Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Health Services Research, 2022, 22, 114. | 0.9 | 5 |
| 9 | Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. International Journal of Technology Assessment in Health Care, 2022, 38, e13. | 0.2 | 78 |
| 10 | Estándares Consolidados de Reporte de Evaluaciones Económicas Sanitarias: adaptación al español de la lista de comprobación CHEERS 2022. Value in Health Regional Issues, 2022, 27, 110-114. | 0.5 | 4 |
| 11 | Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value in Health, 2022, 25, 3-9. | 0.1 | 254 |
| 12 | Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. MDM Policy and Practice, 2022, 7, 238146832110610. | 0.5 | 1 |
| 13 | Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. Health Policy OPEN, 2022, 3, 100063. | 0.5 | 11 |
| 14 | Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Medicine, 2022, 20, 23. | 2.3 | 73 |
| 15 | Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Applied Health Economics and Health Policy, 2022, 20, 213. | 1.0 | 12 |
| 16 | Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. European Journal of Health Economics, 2022, 23, 1309-1317. | 1.4 | 9 |
| 17 | Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 146-155. | 0.5 | 3 |
| 18 | Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Clinical Therapeutics, 2022, 44, 158-168. | 1.1 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Delivering precision oncology to patients with cancer. <i>Nature Medicine</i> , 2022, 28, 658-665. | 15.2 | 125 |
| 20 | Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, . | 0.2 | 8 |
| 21 | Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force. <i>Value in Health</i> , 2022, 25, 869-886. | 0.1 | 11 |
| 22 | Redefining Health Technology Assessment: A Comment on "The New Definition of Health Technology Assessment: A Milestone in International Collaboration". <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, . | 0.2 | 4 |
| 23 | Optimizing the delivery of genetic and advanced diagnostic testing in the province of Ontario: challenges and implications for laboratory technology assessment and management in decentralized healthcare systems. <i>Journal of Medical Economics</i> , 2022, 25, 993-1004. | 1.0 | 1 |
| 24 | Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. <i>European Journal of Health Economics</i> , 2021, 22, 723-733. | 1.4 | 7 |
| 25 | Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT). <i>Pharmacoeconomics</i> , 2021, 39, 1075-1084. | 1.7 | 0 |
| 26 | Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients. <i>Current Oncology</i> , 2021, 28, 5278-5294. | 0.9 | 5 |
| 27 | Value assessment of oncology drugs using a weighted criterion-based approach. <i>Cancer</i> , 2020, 126, 1530-1540. | 2.0 | 13 |
| 28 | Systematic Review of Economic Evaluations of Services Provided by Community Pharmacists. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 375-392. | 1.0 | 3 |
| 29 | Reproducible research practices, openness and transparency in health economic evaluations: study protocol for a cross-sectional comparative analysis. <i>BMJ Open</i> , 2020, 10, e034463. | 0.8 | 27 |
| 30 | Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0240584. | 1.1 | 36 |
| 31 | Citation impact was highly variable for reporting guidelines of health research: a citation analysis. <i>Journal of Clinical Epidemiology</i> , 2020, 127, 96-104. | 2.4 | 22 |
| 32 | Gross profits of Canadian pharmacies: A changing policy regime. <i>Healthcare Management Forum</i> , 2020, 33, 228-232. | 0.6 | 1 |
| 33 | Reporting guidelines of health research studies are frequently used inappropriately. <i>Journal of Clinical Epidemiology</i> , 2020, 122, 87-94. | 2.4 | 52 |
| 34 | Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics. <i>Clinical and Experimental Allergy</i> , 2020, 50, 442-452. | 1.4 | 18 |
| 35 | Health Utility Book (HUB) "Cancer: Protocol for a Systematic Literature Review of Health State Utility Values in Cancer. <i>MDM Policy and Practice</i> , 2019, 4, 238146831985259. | 0.5 | 1 |
| 36 | Variability in aneurysm sac regression after endovascular aneurysm repair based on a comprehensive registry of patients in Eastern Ontario. <i>Journal of Vascular Surgery</i> , 2019, 70, 1469-1478. | 0.6 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | A Beginner's Guide to Understanding Curative Therapies. Value in Health, 2019, 22, 619-620. | 0.1 | 2 |
| 38 | Use of Real-World Data Sources for Canadian Drug Pricing and Reimbursement Decisions: Stakeholder Views and Lessons for Other Countries. International Journal of Technology Assessment in Health Care, 2019, 35, 181-188. | 0.2 | 5 |
| 39 | Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB). Medical Decision Making, 2019, 39, 371-379. | 1.2 | 14 |
| 40 | Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. Value in Health, 2019, 22, 13-20. | 0.1 | 76 |
| 41 | Systematic review and MAIC of OCS reduction with biologic asthma treatments. , 2019, , . | | 0 |
| 42 | Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching. Applied Health Economics and Health Policy, 2018, 16, 279-288. | 1.0 | 7 |
| 43 | Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment. Pharmacoeconomics, 2018, 36, 7-15. | 1.7 | 11 |
| 44 | Evidence and its impact on pharmacy practice: Donâ€™t be â€œevidence-illiterateâ€. Canadian Pharmacists Journal, 2018, 151, 357-358. | 0.4 | 2 |
| 45 | Economic evaluations of eHealth technologies: A systematic review. PLoS ONE, 2018, 13, e0198112. | 1.1 | 65 |
| 46 | Matching-adjusted indirect comparison of benralizumab <i>versus</i> interleukin-5 inhibitors for the treatment of severe asthma: a systematic review. European Respiratory Journal, 2018, 52, 1801393. | 3.1 | 74 |
| 47 | Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data. Allergy, Asthma and Clinical Immunology, 2018, 14, 15. | 0.9 | 16 |
| 48 | PC030 Device-Specific Variability in Aneurysm Sac Regression Following Endovascular Aneurysm Repair Based on a Comprehensive Registry of Patients in Eastern Ontario. Journal of Vascular Surgery, 2017, 65, 148S. | 0.6 | 0 |
| 49 | Device-Specific Variability in Aneurysm Sac Regression After Endovascular Aneurysm Repair Based on a Comprehensive Registry of Patients in Eastern Ontario. Journal of Vascular Surgery, 2017, 66, e73-e74. | 0.6 | 0 |
| 50 | Roteiro para relato de estudos de avaliaÃ§Ã£o econÃ´mica. Epidemiologia E Servicos De Saude: Revista Do Sistema Unico De Saude Do Brasil, 2017, 26, 895-898. | 0.3 | 5 |
| 51 | Systematic review and network meta-analysis of stroke-prevention treatments in patients with atrial fibrillation. Clinical Pharmacology: Advances and Applications, 2016, Volume 8, 93-107. | 0.8 | 35 |
| 52 | CHANGING HEALTH TECHNOLOGY ASSESSMENT PARADIGMS?. International Journal of Technology Assessment in Health Care, 2016, 32, 191-199. | 0.2 | 34 |
| 53 | Using Phase-Based Costing of Real-World Data to Inform Decisionâ€™Analytic Models for Atrial Fibrillation. Applied Health Economics and Health Policy, 2016, 14, 313-322. | 1.0 | 6 |
| 54 | MEDICAL DEVICE PRICES IN ECONOMIC EVALUATIONS. International Journal of Technology Assessment in Health Care, 2015, 31, 86-89. | 0.2 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | David Sackett 1934â€“2015. Value in Health, 2015, 18, 549. | 0.1 | 0 |
| 56 | How do we value a cure?. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 551-555. | 0.7 | 12 |
| 57 | Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration. Pharmacoeconomics, 2015, 33, 535-536. | 1.7 | 7 |
| 58 | How do Economic Evaluations Inform Health Policy Decisions for Treatment and Prevention in Canada and the United States?. Applied Health Economics and Health Policy, 2015, 13, 273-279. | 1.0 | 11 |
| 59 | A Systematic Review of Cost-Sharing Strategies Used within Publicly-Funded Drug Plans in Member Countries of the Organisation for Economic Co-Operation and Development. PLoS ONE, 2014, 9, e90434. | 1.1 | 35 |
| 60 | Incorporating economic evaluation into immunization decision making in Canada: a workshop. Expert Review of Vaccines, 2014, 13, 1291-1296. | 2.0 | 4 |
| 61 | Evolution of Drug Reimbursement in Canada: The Pan-Canadian Pharmaceutical Alliance for New Drugs. Value in Health, 2014, 17, 888-894. | 0.1 | 23 |
| 62 | HEALTH TECHNOLOGY ASSESSMENT AND PERSONALIZED MEDICINE: ARE ECONOMIC EVALUATION GUIDELINES SUFFICIENT TO SUPPORT DECISION MAKING?. International Journal of Technology Assessment in Health Care, 2014, 30, 179-187. | 0.2 | 30 |
| 63 | ADAPTIVE APPROACHES TO LICENSING, HEALTH TECHNOLOGY ASSESSMENT, AND INTRODUCTION OF DRUGS AND DEVICES. International Journal of Technology Assessment in Health Care, 2014, 30, 241-249. | 0.2 | 16 |
| 64 | A Questionnaire to Assess the Relevance and Credibility of Observational Studies to Inform Health Care Decision Making:Â€An ISPOR-AMCP-NPC Good Practice Task Force Report. Value in Health, 2014, 17, 143-156. | 0.1 | 96 |
| 65 | A Synthesis of Drug Reimbursement Decision-Making Processes in Organisation for Economic Co-operation and Development Countries. Value in Health, 2014, 17, 98-108. | 0.1 | 57 |
| 66 | Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Cost Effectiveness and Resource Allocation, 2013, 11, 6. | 0.6 | 264 |
| 67 | Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMC Medicine, 2013, 11, 80. | 2.3 | 185 |
| 68 | Consolidated Health Economic Evaluation Reporting Standards (CHEERS)â€”Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value in Health, 2013, 16, 231-250. | 0.1 | 1,657 |
| 69 | Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. Pharmacoeconomics, 2013, 31, 361-367. | 1.7 | 124 |
| 70 | Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. Value in Health, 2013, 16, e1-e5. | 0.1 | 513 |
| 71 | Lista de Comprobaci3n CHEERS11Consolidated Health Economic Evaluation Reporting Standards. en EspaÃ±ol: EstÃ¡ndares Consolidados de Reporte de Evaluaciones Econ3micas Sanitarias. Value in Health Regional Issues, 2013, 2, 335-337. | 0.5 | 0 |
| 72 | Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. Clinical Therapeutics, 2013, 35, 356-363. | 1.1 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. European Journal of Health Economics, 2013, 14, 367-372. | 1.4 | 191 |
| 74 | Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BJOG: an International Journal of Obstetrics and Gynaecology, 2013, 120, 765-770. | 1.1 | 36 |
| 75 | Identifying strategies to improve diabetes care in Alberta, Canada, using the knowledge-to-action cycle. CMAJ Open, 2013, 1, E142-E150. | 1.1 | 6 |
| 76 | Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Journal of Medical Economics, 2013, 16, 713-719. | 1.0 | 18 |
| 77 | CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS (CHEERS) STATEMENT. International Journal of Technology Assessment in Health Care, 2013, 29, 117-122. | 0.2 | 281 |
| 78 | Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ, The, 2013, 346, f1049-f1049. | 3.0 | 1,082 |
| 79 | Statins for primary prevention. Cmaj, 2012, 184, 791.2-792. | 0.9 | 1 |
| 80 | Trends in the utilization of endovascular therapy for elective and ruptured abdominal aortic aneurysm procedures in Canada. Journal of Vascular Surgery, 2012, 56, 1518-1526.e1. | 0.6 | 17 |
| 81 | Wait times among patients with symptomatic carotid artery stenosis requiring carotid endarterectomy for stroke prevention. Journal of Vascular Surgery, 2012, 56, 661-667.e2. | 0.6 | 20 |
| 82 | Guidelines for Health Technologies: Specific Guidance for Oncology Products in Canada. Value in Health, 2012, 15, 580-585. | 0.1 | 14 |
| 83 | THE EFFECT OF ENGLISH-LANGUAGE RESTRICTION ON SYSTEMATIC REVIEW-BASED META-ANALYSES: A SYSTEMATIC REVIEW OF EMPIRICAL STUDIES. International Journal of Technology Assessment in Health Care, 2012, 28, 138-144. | 0.2 | 804 |
| 84 | RR12. Trends in the Utilization of Endovascular Therapy for Elective and Ruptured Abdominal Aortic Aneurysm Procedures across Canada: A Cohort Study. Journal of Vascular Surgery, 2011, 53, 97S-98S. | 0.6 | 0 |
| 85 | Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. Cmaj, 2011, 183, E1189-E1202. | 0.9 | 112 |
| 86 | Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk. Cmaj, 2011, 183, E1180-E1188. | 0.9 | 32 |
| 87 | Editorial [Sentence First, Verdict Afterwards: Using Value of Information Analysis to Inform Decisions about Pharmacogenomic Test Adoption and Research]. Current Pharmacogenomics and Personalized Medicine, 2010, 8, 167-170. | 0.2 | 5 |
| 88 | Priority setting for health technology assessment at CADTH. International Journal of Technology Assessment in Health Care, 2010, 26, 341-347. | 0.2 | 55 |
| 89 | Health technology assessment in Canada. International Journal of Technology Assessment in Health Care, 2009, 25, 53-60. | 0.2 | 30 |
| 90 | Health Technology Assessment: A Review of International Activity and Examples of Approaches With Computed Tomographic Colonography. Journal of the American College of Radiology, 2009, 6, 343-352. | 0.9 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 91 | Priority setting for health technology assessments: A systematic review of current practical approaches. <i>International Journal of Technology Assessment in Health Care</i> , 2007, 23, 310-315. | 0.2 | 114 |
| 92 | Priority setting for health technology assessments: A systematic review of current practical approaches. <i>International Journal of Technology Assessment in Health Care</i> , 2007, 23, 519-519. | 0.2 | 1 |
| 93 | Long acting β_2 agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trials. <i>BMC Pulmonary Medicine</i> , 2004, 4, 7. | 0.8 | 10 |
| 94 | A general affinity method to purify peroxidase-tagged antibodies. <i>Journal of Immunological Methods</i> , 2001, 249, 33-41. | 0.6 | 15 |